ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

EXAS EXACT Sciences Corporation

61.41
0.00 (0.00%)
May 07 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 61.31
Ask Price 62.60
News -
Day High

Low
56.05

52 Week Range

High
100.77

Day Low
Company Name Stock Ticker Symbol Market Type
EXACT Sciences Corporation EXAS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 61.41 20:00:00
Open Price Low Price High Price Close Price Prev Close
61.41
Trades Volume Avg Volume 52 Week Range
0 0 - 56.05 - 100.77
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 61.41 USD

EXACT Sciences Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
11.15B 181.53M - 2.58B -204.15M -1.12 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

EXACT Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No EXAS Message Board. Create One! See More Posts on EXAS Message Board See More Message Board Posts

Historical EXAS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week59.0663.9957.9761.591,992,6612.353.98%
1 Month71.8273.8157.552964.192,374,793-10.41-14.49%
3 Months60.2879.6256.0564.322,534,9051.131.87%
6 Months64.7479.6256.0565.142,094,303-3.33-5.14%
1 Year67.30100.7756.0572.081,854,636-5.89-8.75%
3 Years104.40133.9929.2767.871,941,306-42.99-41.18%
5 Years103.94159.5429.2780.521,905,273-42.53-40.92%

EXACT Sciences Description

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.

Your Recent History

Delayed Upgrade Clock